Your browser cookies must be enabled in order to apply for this job. Please contact support@jobscore.com if you need further instruction on how to do that.

Director Computational Chemistry

R&D | San Diego, CA | Full Time

Job Description

We are looking for an experienced Computational Chemistry lead for an emerging global drug discovery company. This Director will be critical for shaping and implementing the company’s computational chemistry approach and engage and influence the medicinal chemistry team. This person will provide a clear vision of how computational chemistry can be applied within a small biotech setting.

 

The director needs to have specific experience in applying computational chemistry for structure-guided drug discovery. You should be well versed in the application of computational models to medicinal chemistry design cycles and development of bespoke models to address challenges faced by the project team. You will conceive and execute on strategic vision as for leveraging structural information of peptide receptors to discover small molecule drugs. This Director will determine opportunities for developing and implementing novel methodology to solve challenging problems in prediction and design of molecular properties.

 

In this role you will have the opportunity to conceptualize, design and lead the computational chemistry approach and engage and influence the medicinal chemistry team. You should be familiar with leading computational chemistry software platforms and be able to design, develop and implement novel algorithms as necessary. You will build and manage the computational chemistry and biology group through recruitment of key members in the US and abroad. You will also collaborate closely with the structural biology and medicinal chemistry teams to support discovery research and position assets for preclinical development, Phase 1 / Phase 2 clinical trials, aligning R&D with the Company’s corporate goals.

  

You will be joining an experienced team of international drug innovators financed by top-tier global life sciences investors. An IPO is anticipated next year.